AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-08. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
=== Traditional methods === Mazatec shamans crush the leaves to extract leaf juices from about 20 to 80 or more fresh leaves (i.e. about 50–200 g or 2–7 oz). They usually mix these juices with water to create an infusion or 'tea' which they drink to induce visions in ritual healing ceremonies. Chewing and swallowing a large number of fresh leaves is the other Mazatec method. Oral consumption of the leaf makes the effects come on more slowly, over a period of 10 to 20 minutes. The experience, from the onset of effects, lasts from about 30 minutes up to one and a half hours. Doses for chewing vastly exceed doses used for smoking. By calculating the concentrations per leaf ("an average concentration of 2.45 mg per gram" of leaf), the average weight per leaf ("about 50 g" per 20 leaves, or 2.5 g/leaf), and the standard dose for chewing (about 8–28 leaves), the doses can range from about 50 mg to 172 mg.
== Adverse effects == The most common adverse drug reactions include headache, nasal and throat irritation (nasopharyngitis), urinary tract infection, nausea, and fever (pyrexia). The most common side effect in clinical trials was headache (in about 10% of people who take it). Less common side effects (between 1 and 10% of people) included unspecific symptoms such as dizziness, fatigue, and nausea, but also depression. Possible rare side effects could not be assessed because of the low number of subjects in the clinical trials in which adverse effects were measured.
== Properties == Native silk fibre is both strong and tough, and silkworm silk spun under controlled conditions approaches spider dragline silk in strength. Regenerated silk rarely matches it, because reprocessing disrupts the ordered molecular alignment produced during natural spinning, and the reconstituted material is correspondingly weaker. The extent of this loss depends on the format and the beta-sheet content, and matching the properties of native silk in regenerated form has not yet been fully resolved. Purified fibroin is well tolerated by living tissue and supports the attachment and growth of many cell types. The mild reaction associated with modern silk biomaterials results largely from purification: when sericin and other residues are removed the response is slight, whereas their presence provokes a stronger reaction. This is a large part of why degumming is emphasised in device manufacture. Many synthetic implants remain essentially inert in the body; silk does not. Protease enzymes such as chymotrypsin cleave it into peptides and amino acids that the body can absorb. The rate of degradation is not fixed; it can be set from a few weeks to more than a year by adjusting the beta-sheet content, the format and the porosity. This allows a scaffold to be designed so that it degrades at approximately the rate at which new tissue forms. Surgical silk is sometimes described as non-degradable, a term that reflects the slow loss of strength of a thick braided suture rather than any permanence of the protein itself.
Sources: en.wikipedia.org
A major part of EU law, and most of the EU's budget, concerns public regulation of enterprise and public services. A basic norm of the Treaty on the Functioning of the EU, in article 345, is that the "Treaties shall in no way prejudice the rules in Member States governing the system of property ownership", meaning the EU remains neutral between private or public ownership, but that it can require common standards. In the cases of education and health, member states generally organise public services and the EU requires free movement. There is a unified European Central Bank that funds private banks, and adopts a common monetary policy for price stability, employment and sustainability. The EU's policies on energy, agriculture and forestry, transport and buildings are crucial to end climate damage and shift completely to clean energy that does not heat the planet. Among these, 33% of the entire EU budget is spent on agricultural subsidies to farm corporations and owners. The EU also has an increasing number of policies to raise standards for communications, the internet, data protection, and online media. It has limited involvement in the military and security, but a Common Foreign and Security Policy.
== Advantages of chemoenzymatic synthesis == -Enzymes are environmentally benign, being completely degraded in the environment. -Most enzymes typically function under mild or biological conditions, which minimizes problems of undesired side-reactions such as decomposition, isomerization, racemization and rearrangement, which often plague traditional methodology. -Enzymes selected for chemoenzymatic synthesis can be immobilized on a solid support. These immobilized enzymes demonstrate improved stability and re-usability. -Through the development of protein engineering, specifically site-directed mutagenesis and directed evolution, enzymes can be modified to enable non-natural reactivity. Modifications may also allow for a broader substrate range, enhance reaction rate or catalyst turnover. -Enzymes exhibit extreme selectivity towards their substrates. Typically enzymes display three major types of selectivity:
== Neuroscience organizations == The largest professional neuroscience organization is the Society for Neuroscience (SFN), which is based in the United States but includes many members from other countries. Since its founding in 1969 the SFN has grown steadily: as of 2010 it recorded 40,290 members from 83 countries. Annual meetings, held each year in a different American city, draw attendance from researchers, postdoctoral fellows, graduate students, and undergraduates, as well as educational institutions, funding agencies, publishers, and hundreds of businesses that supply products used in research. Other major organizations devoted to neuroscience include the International Brain Research Organization (IBRO), which holds its meetings in a country from a different part of the world each year, and the Federation of European Neuroscience Societies (FENS), which holds a meeting in a different European city every two years. FENS comprises a set of 32 national-level organizations, including the British Neuroscience Association, the German Neuroscience Society (Neurowissenschaftliche Gesellschaft), and the French Société des Neurosciences. The first National Honor Society in Neuroscience, Nu Rho Psi, was founded in 2006. Numerous youth neuroscience societies which support undergraduates, graduates and early career researchers also exist, such as Simply Neuroscience and Project Encephalon. In 2013, the BRAIN Initiative was announced in the US.
Sources: en.wikipedia.org
AcF3 + 2 NH3 + H2O → AcOF + 2 NH4F Actinium trichloride is obtained by reacting actinium hydroxide or oxalate with carbon tetrachloride vapors at temperatures above 960 °C (1,760 °F). Similarly to the oxyfluoride, actinium oxychloride can be prepared by hydrolyzing actinium trichloride with ammonium hydroxide at 1,000 °C (1,830 °F). However, in contrast to the oxyfluoride, the oxychloride could well be synthesized by igniting a solution of actinium trichloride in hydrochloric acid with ammonia. Reaction of aluminium bromide and actinium oxide yields actinium tribromide:
Typically, chia seeds are small flattened ovoids measuring on average 2.1 mm × 1.3 mm × 0.8 mm (0.08 in × 0.05 in × 0.03 in), with an average weight of 1.3 mg per seed. They are mottle-colored with brown, gray, black, and white. The seeds are hygroscopic, absorbing up to 12 times their weight in liquid when soaked; they develop a mucilaginous coating that gives them a gel texture. Chia (or chian or chien) has mostly been identified as Salvia hispanica L. Other plants referred to as "chia" include "golden chia" (Salvia columbariae). The seeds of Salvia columbariae are also used for food.
=== Regulatory scrutiny and international expansion (2025–2026) === In June 2025, Hims & Hers acquired the London-based European digital health platform ZAVA for undisclosed cash consideration, extending the company's presence into Germany, France, and Ireland alongside deeper reach into the United Kingdom. In August 2025, Bloomberg reported that the Federal Trade Commission had been investigating the company's advertising claims and subscription cancellation practices for more than a year. On September 9, 2025, the FDA sent Hims & Hers a warning letter as part of a broader enforcement effort targeting more than 100 drug advertisers, faulting the company for statements on its website claiming that its compounded products contained "the same active ingredient" as FDA-approved Ozempic and Wegovy. On February 5, 2026, Hims & Hers introduced a compounded oral semaglutide pill for the first month, undercutting Novo Nordisk's newly approved branded oral Wegovy pill. Novo Nordisk announced its intention to sue the company for patent infringement related to U.S. Patent No. 8,129,343, which protects the semaglutide molecule until December 2031. On February 7, 2026, Hims & Hers announced it would withdraw the compounded oral pill from its platform. Novo Nordisk formally filed the patent infringement suit in the United States District Court for the District of Delaware on February 9, 2026.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.